(Total Views: 593)
 Posted On: 11/24/2020 2:05:46 AM 
  
		  		    Post#  of 716		    
			
		      
  
	$RLFTF  NEURORX AND RELIEF ANNOUNCE INITIAL SUCCESSFUL RESULTS FROM EXPANDED ACCESS USE OF RLF-100™ (AVIPTADIL) IN PATIENTS WITH CRITICAL COVID-19 AND SEVERE COMORBIDITY: 72% SURVIVAL SEEN IN ICU PATIENTS 
 
 
https://relieftherapeutics.com/newsblog/neuro...u-patients
 	
 
https://relieftherapeutics.com/newsblog/neuro...u-patients
 (0)
(0) (0)
(0)
       $MJ
  
    
      
    
   
      			












